The role of polyamines in human cancer: prospects for drug combination therapies.

Simple item page
dc.contributor.authorBachmann, Andre S
dc.date.accessioned2016-10-25T22:44:55Z
dc.date.available2016-10-25T22:44:55Z
dc.date.issued2004-12
dc.description.abstractOrnithine decarboxylase (ODC) and S-adenosylmethionine decarboxylase (AdoMetDC) are two key enzymes in polyamine (PA) biosynthesis and their inhibition leads to PA pool depletion and cell growth arrest. DFMO and SAM486A are specific inhibitors of ODC and AdoMetDC, respectively, and are the only two PA inhibitors, which have been clinically evaluated in Phase II and III cancer trials. However, drug combination therapies expected to potentiate the effects of these drugs have yet to be systematically pursued. Human cancer trials (e.g. for the treatment of neuroblastoma patients) using a DFMO/SAM486A cocktail, possibly combined with current cytotoxic drugs and concomitant with a PA-deficient diet, are warranted.
dc.identifier.issn0017-8594
dc.identifier.pubmed15704548
dc.identifier.urihttp://hdl.handle.net/10524/53497
dc.language.isoeng
dc.subject.meshAmidines/administration & dosage
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols/therapeutic use
dc.subject.meshEflornithine/administration & dosage
dc.subject.meshHumans
dc.subject.meshIndans/administration & dosage
dc.subject.meshNeoplasms/drug therapy/etiology
dc.subject.meshPolyamines/antagonists & inhibitors/metabolism
dc.titleThe role of polyamines in human cancer: prospects for drug combination therapies.
dc.typeArticle
dc.type.dcmiText
prism.number12
prism.pagerange371-4
prism.publicationnameHawaii Medical Journal
prism.volume63

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
2004-12p371-374.pdf
Size:
471.34 KB
Format:
Adobe Portable Document Format
Download

Collections

Hawaii Medical Journal Articles For 2004